BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 10812227)

  • 1. Immunopotentiating of mucosal and systemic antibody responses in mice by intranasal immunization with HLT-combined influenza virosomal vaccine.
    Cusi MG; Lomagistro MM; Valassina M; Valensin PE; Glück R
    Vaccine; 2000 Jun; 18(25):2838-42. PubMed ID: 10812227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influenza virosomes are an efficient delivery system for respiratory syncytial virus-F antigen inducing humoral and cell-mediated immunity.
    Cusi MG; Zurbriggen R; Correale P; Valassina M; Terrosi C; Pergola L; Valensin PE; Glück R
    Vaccine; 2002 Oct; 20(29-30):3436-42. PubMed ID: 12297388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers.
    Stephenson I; Zambon MC; Rudin A; Colegate A; Podda A; Bugarini R; Del Giudice G; Minutello A; Bonnington S; Holmgren J; Mills KH; Nicholson KG
    J Virol; 2006 May; 80(10):4962-70. PubMed ID: 16641287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine.
    Tamura S; Yamanaka A; Shimohara M; Tomita T; Komase K; Tsuda Y; Suzuki Y; Nagamine T; Kawahara K; Danbara H
    Vaccine; 1994 Apr; 12(5):419-26. PubMed ID: 8023550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The adjuvants MF59 and LT-K63 enhance the mucosal and systemic immunogenicity of subunit influenza vaccine administered intranasally in mice.
    Barchfeld GL; Hessler AL; Chen M; Pizza M; Rappuoli R; Van Nest GA
    Vaccine; 1999 Feb; 17(7-8):695-704. PubMed ID: 10067675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nasal or intramuscular immunization of mice with influenza subunit antigen and the B subunit of Escherichia coli heat-labile toxin induces IgA- or IgG-mediated protective mucosal immunity.
    Haan L; Verweij WR; Holtrop M; Brands R; van Scharrenburg GJ; Palache AM; Agsteribbe E; Wilschut J
    Vaccine; 2001 Apr; 19(20-22):2898-907. PubMed ID: 11282201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin.
    Hashigucci K; Ogawa H; Ishidate T; Yamashita R; Kamiya H; Watanabe K; Hattori N; Sato T; Suzuki Y; Nagamine T; Aizawa C; Tamura S; Kurata T; Oya A
    Vaccine; 1996 Feb; 14(2):113-9. PubMed ID: 8852406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers.
    Glück U; Gebbers JO; Glück R
    J Virol; 1999 Sep; 73(9):7780-6. PubMed ID: 10438868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of mutant Escherichia coli heat-labile enterotoxin (LT H44A) as an adjuvant for nasal influenza vaccine.
    Hagiwar Y; Tsuji T; Iwasaki T; Kadowaki S; Asanuma H; Chen Z; Komase K; Suzuki Y; Aizawa C; Kurata T; Tamura S
    Vaccine; 2001 Feb; 19(15-16):2071-9. PubMed ID: 11228379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A proposal for safety standards for human use of cholera toxin (or Escherichia coli heat-labile enterotoxin) derivatives as an adjuvant of nasal inactivated influenza vaccine.
    Tamura SI; Kurata T
    Jpn J Infect Dis; 2000 Jun; 53(3):98-106. PubMed ID: 10957706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative analysis of the mucosal adjuvanticity of the type II heat-labile enterotoxins LT-IIa and LT-IIb.
    Martin M; Metzger DJ; Michalek SM; Connell TD; Russell MW
    Infect Immun; 2000 Jan; 68(1):281-7. PubMed ID: 10603399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal immunization of mice with influenza vaccine in combination with the adjuvant LT-R72 induces potent mucosal and serum immunity which is stronger than that with traditional intramuscular immunization.
    Barackman JD; Ott G; O'Hagan DT
    Infect Immun; 1999 Aug; 67(8):4276-9. PubMed ID: 10417205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a mucosal adjuvant.
    Glück R; Mischler R; Durrer P; Fürer E; Lang AB; Herzog C; Cryz SJ
    J Infect Dis; 2000 Mar; 181(3):1129-32. PubMed ID: 10720540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucosal immunoadjuvant activity of recombinant Escherichia coli heat-labile enterotoxin and its B subunit: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with influenza virus surface antigen.
    Verweij WR; de Haan L; Holtrop M; Agsteribbe E; Brands R; van Scharrenburg GJ; Wilschut J
    Vaccine; 1998 Dec; 16(20):2069-76. PubMed ID: 9796066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged protection against Intranasal challenge with influenza virus following systemic immunization or combinations of mucosal and systemic immunizations with a heat-labile toxin mutant.
    Zhou F; Goodsell A; Uematsu Y; Vajdy M
    Clin Vaccine Immunol; 2009 Apr; 16(4):471-8. PubMed ID: 19193829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucosal delivery of a respiratory syncytial virus CTL peptide with enterotoxin-based adjuvants elicits protective, immunopathogenic, and immunoregulatory antiviral CD8+ T cell responses.
    Simmons CP; Hussell T; Sparer T; Walzl G; Openshaw P; Dougan G
    J Immunol; 2001 Jan; 166(2):1106-13. PubMed ID: 11145691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intranasal immunization with live recombinant Lactococcus lactis combined with heat-labile toxin B subunit protects chickens from highly pathogenic avian influenza H5N1 virus.
    Lei H; Peng X; Shu H; Zhao D
    J Med Virol; 2015 Jan; 87(1):39-44. PubMed ID: 24861477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranasal immunisation with influenza-ISCOM induces strong mucosal as well as systemic antibody and cytotoxic T-lymphocyte responses.
    Sjölander S; Drane D; Davis R; Beezum L; Pearse M; Cox J
    Vaccine; 2001 Jul; 19(28-29):4072-80. PubMed ID: 11427284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines.
    Asahi Y; Yoshikawa T; Watanabe I; Iwasaki T; Hasegawa H; Sato Y; Shimada S; Nanno M; Matsuoka Y; Ohwaki M; Iwakura Y; Suzuki Y; Aizawa C; Sata T; Kurata T; Tamura S
    J Immunol; 2002 Mar; 168(6):2930-8. PubMed ID: 11884464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humoral and cellular immune responses in the murine respiratory tract following oral immunization with cholera toxin or Escherichia coli heat-labile enterotoxin.
    Ruedl C; Rieser C; Kofler N; Wick G; Wolf H
    Vaccine; 1996 Jun; 14(8):792-8. PubMed ID: 8817827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.